Market Research Logo

NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2016 Update

Summary

NovoCure Ltd (NovoCure) is an oncology company that focuses on the development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in various types of cancer indications such as ovarian cancer, malignant melanoma, hepatocellular carcinoma, breast cancer and small cell lung cancer, among others. Novocure also offers products for other indications such as glioblastoma and diagnosed glioblastoma. The company operates along with its subsidiaries located in New Hampshire, the US; and Berlin, Germany. It owns and operates a research centre in Haifa, Israel. The company also has presence in Japan and Switzerland. NovoCure is headquartered in Jersey, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company NovoCure Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio


NovoCure Ltd Company Overview
NovoCure Ltd Company Snapshot
NovoCure Ltd Pipeline Products and Clinical Trials Overview
NovoCure Ltd – Pipeline Analysis Overview
Key Facts
NovoCure Ltd - Major Products and Services
NovoCure Ltd Pipeline Products by Development Stage
NovoCure Ltd Clinical Trials by Trial Status
NovoCure Ltd Pipeline Products Overview
Optune - Brain Metastasis
Optune - Brain Metastasis Product Overview
Optune - Brain Metastasis Clinical Trial
Optune - Breast Cancer
Optune - Breast Cancer Product Overview
Optune - Cervical Cancer
Optune - Cervical Cancer Product Overview
Optune - Colorectal Carcinoma
Optune - Colorectal Carcinoma Product Overview
Optune - Gastric Adenocarcinoma
Optune - Gastric Adenocarcinoma Product Overview
Optune - Hepatocellular Carcinoma
Optune - Hepatocellular Carcinoma Product Overview
Optune - Liver Metastases
Optune - Liver Metastases Product Overview
Optune - Malignant Melanoma
Optune - Malignant Melanoma Product Overview
Optune - Mesothelioma
Optune - Mesothelioma Product Overview
Optune - Ovarian Cancer
Optune - Ovarian Cancer Product Overview
Optune - Pancreatic Cancer
Optune - Pancreatic Cancer Product Overview
Optune - Prostate Cancer
Optune - Prostate Cancer Product Overview
Optune - Renal Adenocarcinoma
Optune - Renal Adenocarcinoma Product Overview
Optune - Small Cell Lung Cancer
Optune - Small Cell Lung Cancer Product Overview
Optune - Squamous Non-Small Cell Lung Cancer
Optune - Squamous Non-Small Cell Lung Cancer Product Overview
Optune - Urinary Transitional Cell Carcinoma
Optune - Urinary Transitional Cell Carcinoma Product Overview
NovoCure Ltd - Key Competitors
NovoCure Ltd - Key Employees
NovoCure Ltd - Key Employee Biographies
NovoCure Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
NovoCure Ltd, Recent Developments
Dec 19, 2016: Novocure’s Optune (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma
Dec 12, 2016: Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel and Gemcitabine may be Safe as First-Line Treatment and may Improve One-Year Survival Rate of Patients with Advanced Pancreatic
Dec 12, 2016: Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer
Dec 08, 2016: Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
Nov 18, 2016: Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates
Nov 03, 2016: United Healthcare Issues Positive Coverage Decision for Optune
Nov 02, 2016: Novocure Reports Third Quarter 2016 Financial Results and Provides Company Update
Oct 12, 2016: Novocure Enrolls First Patient in Phase 3 Pivotal Brain Metastases Trial
Sep 19, 2016: CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma
Sep 15, 2016: Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
NovoCure Ltd Pipeline Products and Clinical Trials Overview
NovoCure Ltd Pipeline Products by Equipment Type
NovoCure Ltd Pipeline Products by Indication
NovoCure Ltd Clinical Trials by Trial Status
NovoCure Ltd, Key Facts
NovoCure Ltd, Major Products and Services
NovoCure Ltd Number of Pipeline Products by Development Stage
NovoCure Ltd Pipeline Products Summary by Development Stage
NovoCure Ltd Clinical Trials by Trial Status
NovoCure Ltd Clinical Trials Summary
Optune - Brain Metastasis - Product Status
Optune - Brain Metastasis - Product Description
Optune - Brain Metastasis - A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients with 1-5 Brain Metastases Following Optimal Standard Local Treatment
Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Optune - Brain Metastasis - Pivotal, Open-label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
Optune - Breast Cancer - Product Status
Optune - Breast Cancer - Product Description
Optune - Cervical Cancer - Product Status
Optune - Cervical Cancer - Product Description
Optune - Colorectal Carcinoma - Product Status
Optune - Colorectal Carcinoma - Product Description
Optune - Gastric Adenocarcinoma - Product Status
Optune - Gastric Adenocarcinoma - Product Description
Optune - Hepatocellular Carcinoma - Product Status
Optune - Hepatocellular Carcinoma - Product Description
Optune - Liver Metastases - Product Status
Optune - Liver Metastases - Product Description
Optune - Malignant Melanoma - Product Status
Optune - Malignant Melanoma - Product Description
Optune - Mesothelioma - Product Status
Optune - Mesothelioma - Product Description
Optune - Ovarian Cancer - Product Status
Optune - Ovarian Cancer - Product Description
Optune - Pancreatic Cancer - Product Status
Optune - Pancreatic Cancer - Product Description
Optune - Prostate Cancer - Product Status
Optune - Prostate Cancer - Product Description
Optune - Renal Adenocarcinoma - Product Status
Optune - Renal Adenocarcinoma - Product Description
Optune - Small Cell Lung Cancer - Product Status
Optune - Small Cell Lung Cancer - Product Description
Optune - Squamous Non-Small Cell Lung Cancer - Product Status
Optune - Squamous Non-Small Cell Lung Cancer - Product Description
Optune - Urinary Transitional Cell Carcinoma - Product Status
Optune - Urinary Transitional Cell Carcinoma - Product Description
NovoCure Ltd, Key Employees
NovoCure Ltd, Key Employee Biographies
Table 2: NovoCure Ltd, Other Locations
NovoCure Ltd, Subsidiaries
List of Figures
NovoCure Ltd Pipeline Products by Development Stage
NovoCure Ltd Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report